Anticoagulation therapy is often indicated for the treatment and prevention of venous thromboembolism (VTE). Despite advances in anticoagulant management with parenteral anticoagulants and vitamin K antagonists, limitations to their use still exists, leading to investigation of alternative anticoagulants such as factor Xa inhibitors and direct thrombin inhibitors. To date, 3 target-specific oral anticoagulants (TSOACs) are Food and Drug Administration approved; several other agents are currently in development to optimize VTE management and minimize bleeding risks. The objective of this systematic review article is to provide clinicians an overview of the clinical evidence on the investigational TSOACs for the treatment and prevention of VTE. Of the agents in development, edoxaban holds the most promise due to robust data supporting its clinical benefit with a similar bleeding risk to currently approved agents. Clinicians should understand the TSOACs under investigation, since differences in pharmacokinetics and pharmacodynamics may influence clinical decision making and agent selection for management of VTE. Currently, no direct comparisons between TSOACs have been conducted. Agents under investigation have yet to overcome the major limitations of the currently existing TSOACs. Further studies are necessary to clarify which TSOAC agent is best for management of VTE in clinical practice.
KearonCAklEAComerotaAJ. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e419–e494S.
2.
HuttenBAPrinsMH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev. 2006;25(1):CD001367.
3.
AgenoWGallusASWittkowskyA. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e44–e88S.
4.
WhitlonDSSadowskiJASuttieJW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry. 1978;17(8):1371–1377.
5.
WittkowskyAK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med. 2003;3(3):221–230.
6.
StangierJ. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285–295.
7.
StangierJStahleHRathgenK. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008;48(12):1411–1419.
8.
KubitzaDBeckaMWensingG. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873–880.
9.
KubitzaDBecakMRothA. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008;24(10):2757–2765.
10.
RaghavanNFrostCEYuZ. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74–81.
11.
Hokusai-VTE Investigators; BüllerHRDécoususHGrossoMA. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–1415.
12.
ZahirHMatsushimaNHalimAB. Edoxaban administration following enoxaparin: a pharmacodynamics, pharmacokinetic, and tolerability assessment in human subjects. Thromb Haemost. 2012;108(1):166–175.
13.
BathalaMSMasumotoHOgumaT. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40(12):2250–2255.
14.
RohatagiSMendellJKastrissiosH. Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery. Thromb Haemost. 2012;108(5):887–895.
15.
RaskobGCohenATErikssonBI. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. a randomised double-blind dose-response study. Thromb Haemost. 2010;104(3):642–649.
16.
MendellJNoveckRJShiM. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. Br J Clin Pharmacol. 2012;75(4):966–978.
17.
FujiTFujitaSKawaiY. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Thromb Res. 2014;133(6):1016–1022.
18.
OgataKMendell-HarayJTachibanaM. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743–753.
19.
WeitzJLEikelboomJWSamamaMM. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e120–e51S.
20.
ErikssonBIDahlOERosencherN. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949–956.
21.
RE-MOBILIZE Writing Committee, GinsbergJSDavidsonBLCompPC. Oral thrombin inhibitor dabigatran etexilate vs. North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24(1):1–9.
22.
ErikssonBIDahlOERosencherN. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178–2185.
23.
SchulmanSKearonCKakkarAK. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–2352.
24.
SchulmanSKearonCKakkarAK. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709–718.
25.
TurpieAGLassenMRDavidsonBL. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomized trial. Lancet. 2009;373(9676):1673–1680.
26.
LassenMRAgenoWBorrisLC. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776–2786.
27.
KakkarAKBrennerBDahlOR. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet. 2008;372(9632):31–39.
28.
EINSTEIN Investigators; BauersachsRBerkowitzSDBrennerB. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–2510.
29.
EINSTEIN-PE Investigators, BullerHRPrinsMHLensinAW. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–1297.
30.
LassenMRRaskobGEGallusA. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet. 2010;375(9717):807–815.
31.
AgnelliGBullerHRCohenA. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708.
32.
GoldhaberSZLeizorovicsAKakkarAK. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167–2177.
33.
HaasSSchellongS. New anticoagulants: from bench to bedside. Haemostaseologie. 2007;27(1):41–47.
34.
FujiTFujitaSTachibanaS. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost. 2010;8(11):2458–2468.
35.
KurodaYHirayamaCHotodaH. Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery. Vasc Health Risk Manag. 2013;9:593–598.
36.
TurpieAGGBauerKADavisonBL. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost. 2009;101(1):68–76.
37.
WeitzJICaoCErikssonBI. A dose-finding study with TAK-442, an oral factor Xa inhibitor in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010;104(6):1150–1157.
38.
AgnelliGHasSGinsbergJS. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost. 2007;5(4):746–753.
39.
DavieEWFujikawaK. Basic mechanisms in blood coagulation. Annu Rev Biochem. 1975;44:799–829.
40.
OsterudBRapaportSI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA. 1977;74(12):5260–5264.
41.
BenedictCRRyanJWolitzkyB. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest. 1991;88:1760–1765.
42.
SpanierTBOxMCMinanovOP. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. J Thoracic Cardiovasc Surg. 1998;115(5):1179–1188.
43.
FeuersteinGZPatelAToomeyJR. Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. Arterioscler Thromb Vasc Biol. 1999;19(10):2554–2562.
44.
ToomeyJRValocikREKosterPF. Inhibition of factor IXa is protective in a rat model of thromboembolic stroke. Stroke. 2002;33(2):578–585.
45.
SpanierTBChenJMOzMC. Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1998;116(5):860–869.
46.
RefinoCJJeetSDeGuzmanL. A human antibody that inhibits factor IX/IXa function potently inhibits arterial thrombosis without increasing bleeding. Arterioscler Thromb Vasc Biol. 2002;22(3):517–522.
47.
RusconiCPScardinoELayzerJ. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature. 2002;419(6902):90–94.
48.
DykeCKSteinhublSRKleimanNS. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation. 2006;114(23):2490–2497.
49.
ThompsonARChenSH. Characterization of factor IX defects in hemophilia B patients. Methods Enzymol. 1993;222:143–169.
50.
SramekAKriekMRosendaalFR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet. 2003;362(9381):351–354.
51.
AhmadSSLondonFSWalshPN. Binding studies of the enzyme (factor IXa) with the cofactor (factor VIIIa) in the assembly of factor X activating complex on the activated platelet surface. J Thromb Haemost. 2003;1(11):2348–2355.
52.
ErikssonBIDahlORLassenMR. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008;6(3):457–463.
53.
SiegalDMCukerA. Reversal of novel oral anticoagulants in patients with major bleeding. J Thromb Thrombolysis. 2013;35(3):391–398.
54.
LuGPPengLHollenbachSJ. Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors. J Thromb Haemost. 2009;17:309.
55.
Van RynJLitzenburgerTWatermanA. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol. 2011;57:E1130.
56.
SchulmanSKearonCKakkarAK. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med2009;361(24):2342–2352.
57.
ErikssonBIBauerKALassenMR. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345(18):1298–1304.
